In the lawsuit between Daewoong Pharmaceutical and Medytox, the US International Trade Commission (ITC) overturned the final decision in favor of Medytox.
Daewoong Pharmaceutical announced on the 29th that the U.S. International Trade Commission (ITC) had overturned the final decision, including an order to ban the import of Zhubo (Nabota U.S. export name).
The ITC announced on the 28th (US time) that Medytox and AbbVie were overturning the final decision of the US Federal Circuit of Appeals (CAFC) to dismiss the botulinum toxin lawsuit filed against Daewoong Pharmaceutical and Evolus.
Daewoong Pharmaceutical said, “The litigation parties cannot use the decision for other trials in the United States. In the future, we plan to further expand our global market penetration to increase our business value.”
Medytox refuted the decision. The decision to nullify the ITC is the result of Medytox signing two agreements and agreeing to nullify it.
Medytox emphasized, “Even if the judgment is invalidated as stated by the ITC in its opinion, the relevant evidence and judgment are still valid.”
© ‘Global Economic Daily in 5 Languages’ Ajou Economic Daily. Unauthorized reproduction and redistribution prohibited